University of Vermont

The University of Vermont Cancer Center

trials_breast.html

Breast Cancer Clinical Trials

The University of Vermont Cancer Center has many trials specifically focused on breast cancer research.

Status: Active - Recruiting
Study Title:
VCC 0807 – The Effect of Cancer Therapy for Early Breast Cancer on Brain Imaging and Cognitive Function
Purpose: This study will assess the effects of chemotherapy compared to no chemotherapy on memory, perception, language and emotion during functional magnetic resonance imaging (fMRI, a three dimensional picture of the brain using magnetic waves). The goal is to better understand cognitive changes related to cancer and its therapy.
ClinicalTrials.gov Identifier: N/A
Primary/Site/Co Investigator: Kim Dittus, MD
Contact:Suzanne Hoeppner (802) 656-9916
Information: N/A
Institution Number: M09-040 / VCC 0807
Protocol Research Type: Investigator Initiated
Status: Active - Recruiting
Study Title:
The DNA Repair Landscape of Women at Risk for Breast Cancer
Purpose: Resistance to radiation and chemotherapy is believed to be based in the cancer cells ability to repair large amounts of DNA damage in a short period of time. This ability to repair varies by cell type and by individual. This study will advance our understanding of how variations in DNA repair contribute to individual cancer risk and how they drive carcinogenesis in women at an increased risk for breast cancer. Moreover, how this knowledge may be exploited to treat cancer.
ClinicalTrials.gov Identifier: N/A
Primary/Site/Co Investigator: Marie E. Wood, MD
Contact: Jennifer Holmes (802) 847-3453
Information: N/A
Institution Number: M12-218
Protocol Research Type: Investigator Initiated
Status: Active - Recruiting
Study Title:
VCC 0601 – Phase I/II Trial to Evaluate Partial Breast Radiation to the Region of the Lumpectomy Cavity Using Intensity Modulated Radiation Therapy (IMRT) in Elderly Women with Breast Cancer
Purpose: The usual treatment for most women with breast cancer has been the removal of the cancerous lump (breast conserving therapy) followed by daily radiation therapy (a type of X-ray) to the entire breast for 5 to 7 weeks. The purpose of this study is to evaluate whether giving higher daily doses of radiation using intensity modulated radiation (IMRT) in a shorter time (two weeks) can be done safely.
ClinicalTrials.gov Identifier: NCT00337064
Primary/Site/Co Investigator: Ruth Heimann, MD
Contact: Karen Wilson (802) 656-4101
Information: http://www.clinicaltrials.gov/ct2/show/NCT00337064?term=partial+breast+radiation+AND+elderly&rank=1
Institution Number: CHRMS M06-235, VCC 0601
Protocol Research Type: Investigator Initiated
Status: Active - Recruiting
Study Title:
VCC 0901 – Phase I/II Trial to Evaluate Partial Breast Radiation to the Region of the Lumpectomy Cavity Using Intensity Modulated Radiation Therapy (IMRT) in Elderly Women with Breast Cancer
Purpose: The usual treatment for breast cancer removed by lumpectomy consists of 25- 28 radiation treatments to your entire breast followed by 5 - 9 radiation treatments to the excision (lumpectomy) site only.  This study is being done to find out if it is possible to use three dimensional ultrasound (3D US) images to verify the field being treated with radiation is as similar as possible to the planned field.  It is thought that ultrasound images could be collected daily to accurately determine the shape and location of the lumpectomy cavity, which could allow for immediate adjustments in positioning, potentially improving the efficacy of the therapy.
ClinicalTrials.gov Identifier: N/A
Primary/Site/Co Investigator: Ruth Heimann, MD
Contact: Karen Wilson (802) 656-4101
Information: N/A
Institution Number: CHRMS M09-164, VCC 00901
Protocol Research Type: Investigator Initiated
Status: Active - Recruiting
Study Title:
VCC 1109 – An Internet-Based Weight Loss and Exercise Intervention for Breast Cancer Survivors: The IWEB Program
Purpose: The purpose of this study is to test the effectiveness of a behavioral weight loss and exercise intervention delivered via the internet at different cancer centers in New England.  The research is being done because many women who are treated for breast cancer are overweight and treatment for breast cancer is often accompanied by weight gain. Individuals who are overweight may be more likely to have their breast cancer come back. Also women who exercise at least three hours a week seem to have less chance of their cancer coming back. The investigators hope to identify an effective weight loss and exercise intervention for breast cancer survivors that can be easily accessed by many people.
ClinicalTrials.gov Identifier: NCT01728506
Primary/Site/Co Investigator: Kim Dittus, MD
Contact: Karen Wilson (802) 656-4101
Information: http://www.clinicaltrials.gov/ct2/show/NCT01728506?term=NCT01728506&rank=1
Institution Number: CHRMS M12-109, VCC 1109
Protocol Research Type: Investigator Initiated
Status: Active - Recruiting
Study Title:
NSABP B-47 - A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node- Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Purpose: This randomized phase III clinical trial is studying chemotherapy with or without trastuzumab after surgery to see how well they work in treating women with invasive breast cancer. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving chemotherapy after surgery may kill more tumor cells. Monoclonal antibodies, such as trastuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. It is not yet known whether combination chemotherapy is more effective with trastuzumab in treating breast cancer.
ClinicalTrials.gov Identifier: NCT01275677
Primary/Site/Co Investigator: Kim Dittus, MD
Contact: Suzanne Hoeppner (802) 656-9916
Information: www.clinicaltrials.gov/ct2/show/NCT01275677
Institution Number: M11-174 / NSABP B-47
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
VCC 1010 - Low Dose Metronomic Cyclophosphamide and Methotrexate Chemotherapy in Combination With Aspirin in Patients With Stage II-III Breast Cancer Who Fail to Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy
Purpose: Patients with stage II-III breast cancer who do not achieve a pathologic complete response to neoadjuvant chemotherapy at the time of surgery will be treated with oral low dose continuous cyclophosphamide and methotrexate (CM) in combination with aspirin following surgery and radiotherapy. The primary endpoint is to assess toxicity and safety with secondary endpoints of cytokine correlates and relapse free survival (RFS) at 2 years.
ClinicalTrials.gov Identifier: NCT01612247
Primary/Site/Co Investigator: Marie Wood, MD
Contact: Suzanne Hoeppner (802) 656-9916
Information: www.clinicaltrials.gov/ct2/show/NCT01612247
Institution Number: M11-069 / VCC 1010
Protocol Research Type: Investigator Initiated
Status: Active - Recruiting
Study Title:
Z11102 - Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)
Purpose: Breast-conserving surgery is a less invasive type of surgery for breast cancer and may have fewer side effects and improve recovery. Radiation therapy uses high-energy x rays to kill tumor cells. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial studies how well breast-conserving surgery and radiation therapy work in treating patients with multiple ipsilateral breast cancer
ClinicalTrials.gov Identifier: NCT01556243
Primary/Site/Co Investigator: Michelle Sowden, DO
Contact: Suzanne Hoeppner (802) 656-9916
Information: www.clinicaltrials.gov/ct2/show/NCT01556243
Institution Number: M13-052 / Alliance Z11102
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
Platelet Modulation in the Control of Angiogenesis: A Study of Angiogenic and Coagulation Proteins in Patients with Cancer
Purpose:
ClinicalTrials.gov Identifier: NCT01148407
Primary/Site/Co Investigator: Chris E. Holmes, MD
Contact: Karen Wilson (802) 656-4101
Information:http://www.clinicaltrials.gov/ct2/show/NCT01148407
Institution Number: M09-041 / VCC 0806
Protocol Research Type: Investigator Initiated
Status: Active - Recruiting
Study Title: S1007 - A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less
Purpose: The purpose of this study is to determine the effect of chemotherapy in patients with node positive breast cancer who do not have high Recurrence Scores (RS) by Oncotype DX® and to find out if the Oncotype DX® Recurrence Score can help decide whether  patients should receive chemotherapy or not.  This study is being done in patients with lower Recurrence Scores (25 or less).  If the results of the study show that the benefit for getting chemotherapy is dependent on the Recurrence Score, the study should be able to identify a Recurrence Score level where chemotherapy should be considered ( and a recurrence score level where chemotherapy may not be needed).
ClinicalTrials.gov Identifier: NCT01272037
Primary/Site/Co Investigator: Farrah Khan, MD
Contact: Suzanne Hoeppner (802) 656-9916
Information: N/A
Institution Number: M13-117
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title: NSABP – B52 - Testing the addition of hormonal therapy to usual chemotherapy in advanced breast cancer
Purpose: A Randomized Phase III Trial Evaluating  Pathologic Complete Response Rates in Patients with Hormone  Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of  Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation
ClinicalTrials.gov Identifier: NCT02003209
Primary/Site/Co Investigator: Farrah Khan, MD
Contact: Suzanne Hoeppner (802) 656-9916
Information: http://www.clinicaltrials.gov/ct2/show/NCT02003209?term=NSABP+B-52&rank=1
Institution Number: 14-390
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title: A011106 – ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study
Purpose: Endocrine therapy before surgery has become standard of care in postmenopausal women with bulky estrogen receptor positive (ER+) breast cancer because of the improvement in the rate of breast conserving surgeries.  This study has several objectives. One purpose is to determine whether receiving endocrine therapy before surgery with fulvestrant or the combination of anastrozole and fulvestrant, is better than anastrozole alone when given before surgery to shrink the cancer and stop if from growing.  The reason to study fulvestrant alone, or the combination of fulvestrant and anastrozole, before surgery are the results from studies in patients with advanced cancer, which have shown that these treatment approaches may be superior to anastrozole alone, the current standard of care.  This study will help to determine whether fulvestrant, either alone or in combination with anastrozole, should be used in patients with early stage ER+ breast cancer. 
ClinicalTrials.gov Identifier: NCT01953588
Primary/Site/Co Investigator: Farrah Khan, MD
Contact: Suzanne Hoeppner (802) 656-9916
Information: http://www.clinicaltrials.gov/ct2/show/NCT01953588?term=NCT01953588&rank=1
Institution Number: CHRMS  14-392;  Alliance   A011106
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title: A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
Purpose: This open label, randomised, controlled, multi-centre phase III study will assess the efficacy and safety of single agent olaparib vs standard of care based on physician's choice of capecitabine, vinorelbine or eribulin in metastatic breast cancer patients with gBRCA 1/2 mutations.
ClinicalTrials.gov Identifier: NCT02000622
Primary/Site/Co Investigator: Marie Wood, MD
Contact: Hannah Eldred (802) 656-9441
Information: https://clinicaltrials.gov/ct2/show/NCT02000622?term=olaparib+metastatic+breast+cancer&rank=1
Institution Number: CHRMS 14-477
Protocol Research Type: Industry Sponsored
Status: Active - Recruiting
Study Title: SWOG 1202 - A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI)-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer
Purpose: Initial studies suggest that aromatase inhibitors (AIs – given as endocrine therapy to women with breast cancer) are fairly well tolerated medications. However, it has been increasingly recognized that arthralgias (joint pains) are a significant AI-associated toxicity, affecting as many as 50% of patients. A greater than 20% treatment discontinuation rate due to AI-associated arthralgias in a prospective trial of AI therapy was reported. More importantly, up to 20,000 women a year discontinue these potentially life-saving medications because of intolerable arthralgias and myalgias.

No effective pharmacologic therapy has yet been identified for management of these symptoms, as many patients do not experience relief of symptoms with analgesic therapy. The current treatment for AIMSS (AI-associated Musculoskeletal Symptoms) is limited to oral analgesics and exercise, though neither has optimal effect.

Duloxetine is a selective serotonin- and norepinephrine-reuptake inhibitor (SNRI) which is FDA approved for the treatment of major depressive disorder (MDD), diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain, including osteoarthritis (OA) and low back pain.

This is a Phase III randomized, placebo-controlled clinical trial of duloxetine 60 mg daily versus placebo that aims to evaluate the benefit of duloxetine for management of AIMSS and other related symptoms that can impact quality of life, such as depression, anxiety, hot flashes, and sleep quality. We will perform exploratory correlative studies for hypothesis generation. Improvement in treatment-related symptoms may improve persistence with AI therapy, and thereby lead to improved breast cancer outcomes.

Patients who enroll must report the presence of AIMSS during standard therapy with an AI. Patients will have a physical exam and blood work prior to initiating study therapy, as well as submit a mandatory blood sample to the study. Patients will be randomized to receive duloxetine or placebo for 90 days. They will be followed for 6 months after study entry and will be asked to complete several quality of life questionnaires during their participation.

ClinicalTrials.gov Identifier: NCT01598298
Primary/Site/Co Investigator: Farrah Khan, MD
Contact: Suzanne Hoeppner (802) 656-9916
Information: http://www.clinicaltrials.gov/ct2/show/NCT01598298?term=SWOG+1202&rank=1
Institution Number: CHRMS 14-391
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title: VCC 1414: Novel Exercise Modalities to Improve Fatigue and Muscle Function in Cancer Survivors
Purpose: Exercise training is effective at alleviating the negative health effects of cancer and its treatment and improving long-term prognosis, but there are numerous hurdles to disseminating exercise to individuals diagnosed with and being treated for cancer.  The goal of our research is to develop useful exercise interventions that can serve as alternatives to traditional, facility-based exercise programs and extend the benefits of exercise to the broader cancer survivor population.  The goal of this research study is to begin to evaluate whether exercise training via neuromuscular electrical stimulation (NMES) has beneficial effects on skeletal muscle size and function in cancer patients.
ClinicalTrials.gov Identifier: NA
Primary/Site/Co Investigator: Michael Toth, PhD
Contact: Suzanne Hoeppner (802) 656-9916
Information: NA
Institution Number: M14-567
Protocol Research Type: Investigator Initiated
Status: Active - Recruiting
Study Title: VCC 1206: Predictors of Dyspnea/Fatigue Syndrome in Breast Cancer Survivors
Purpose: Fatigue and shortness of breath with activity are common side effect of cancer therapies and can last after cancer therapy is finished.  The purpose of this study is to understand the reasons why fatigue and shortness of breath are so common.  The research project will examine physical measures and how fatigue and shortness of breath feel to you before chemotherapy, at the end of chemotherapy and again after 6 months of being off chemotherapy.  We hope to identify causes of fatigue and shortness of breath to help us determine who is most at risk of becoming fatigue and short of breath.
ClinicalTrials.gov Identifier: NA
Primary/Site/Co Investigator: Kim Dittus, MD, PhD
Contact: Karen Wilson (802) 656-4101
Information: NA
Institution Number: VCC  1206
Protocol Research Type: Investigator Initiated
Status: Active - Recruiting
Study Title: VCC 1311: Behavioral Weight Loss and Exercise After Treatment (BEAT): Predictors of Weight Loss Success in Overweight Breast Cancer Survivors
Purpose: The purpose of this study is to find out how well a behavioral weight loss and exercise intervention works and to understand what factors predict weight loss and exercise success.  The research is being done because many women who are treated for breast cancer are overweight and individuals who are overweight may be more likely to have their breast cancer come back.  We don’t know for sure if weight loss improves outcomes related to breast cancer but we know it has other health benefits.  Women who are more physically active may be less likely to have their breast cancer come back.  We hope to identify how to best tailor weight loss and exercise programs to help breast cancer survivors make the lifestyle changes needed to lose weight and exercise.
ClinicalTrials.gov Identifier: NCT02052115
Primary/Site/Co Investigator: Kim Dittus, MD, PhD
Contact: Karen Wilson (802) 656-4101
Information: https://clinicaltrials.gov/ct2/show/NCT02052115?term=02052115&rank=1
Institution Number: VCC  1311
Protocol Research Type: Investigator Initiated
Status: Active - Recruiting
Study Title: A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
Purpose: The study seeks to evaluate the efficacy and tolerability of veliparib/placebo in combination with carboplatin and paclitaxel in HER2-negative metastatic or locally advanced, unresectable, BRCA-associated breast cancer.
ClinicalTrials.gov Identifier: NCT02163694
Contact: Hannah Eldred (802) 656-9441
Information: http://www.clinicaltrials.gov/ct2/show/NCT02163694?term=abbvie+m12-914&rank=1
Institution Number: CHRMS 14-529
Protocol Research Type: Industry Sponsored
Status: Active - Recruiting
Study Title: RTOG 1119: Phase II Randomized Study of Whole Brain Radiotherapy in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer: A Collaborative Study of RTOG and KROG
Purpose: Lapatinib is a drug that has been approved by the FDA for patients with progressive HER2-positive metastatic breast cancer. However, the combination of brain radiation and lapatinib for the treatment of brain metastases is experimental. The combination is being tested because lapatinib was found to improve the effectiveness of radiation therapy in the laboratory. An early study in patients showed that brain radiation and lapatinib can be combined safely.

The purpose of this study is to compare the effects of adding lapatinib to standard whole brain radiation therapy (WBRT). The study will try to find out whether WBRT or lapatinib plus WBRT is better at safely improving tumor control.  In this study, patients will receive either lapatinib plus WBRT or WBRT alone.
ClinicalTrials.gov Identifier: NCT01622868
Primary/Site/Co Investigator: Deborah Rubin, MD
Contact: Jennifer Holmes (802) 847-3453
Information: https://clinicaltrials.gov/ct2/show/NCT01622868?term=RTOG-1119&rank=1&rank=1
Institution Number: 14-565
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title: S1207:  Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year  of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
Purpose: The purpose of this study is to see whether treatment with everolimus plus hormone treatment after chemotherapy will increase the time without cancer returning in patients diagnosed with breast cancer that demonstrate “high-risk” features (e.g. a high number of positive lymph nodes, HER2 positivity, and/or a high Oncotype DX recurrence score).

The current standard of treatment after chemotherapy is hormone therapy alone.  Everolimus is a drug currently approved for the treatment of patients with advanced or metastatic kidney or breast cancer.  It works by blocking some of the enzymes needed for tumor cell growth.  Previous research in patients with metastatic breast cancer suggests that the addition of everolimus in patients with hormone-receptor positive cancers may provide the most benefit.

ClinicalTrials.gov Identifier: NCT01674140
Primary/Site/Co Investigator: Marie Wood, MD
Contact: Suzanne Hoeppner (802) 656-9916
Information: http://clinicaltrials.gov/ct2/show/NCT01674140?term=s1207&rank=1
Institution Number: 14-566
Protocol Research Type: Cooperative Group
Status: Active - Closed to Accrual
Study Title: RTOG 1173/ECOG 2108 - A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
Purpose: The standard treatment for patients diagnosed with metastatic breast cancer at the time of their initial presentation is the use of chemotherapy, anti-hormone pills, or other medication. Generally, the primary breast tumor is left intact and untreated locally unless it becomes symptomatic (ulceration, pain, etc). 

The primary objective of this study is to determine if treating the primary tumor with surgery with or without radiation in patients who don’t progress following optimal systemic therapy improves overall survival.  Secondary objectives include comparing the time to uncontrolled chest wall disease, overall quality of life, and evaluating the burden of circulating tumor cells at 6 months.

Patients who participate will all receive optimal systemic therapy upfront as determined by their physician (chemotherapy and/or hormonal therapy).  After 4-8 months of systemic therapy, patients who have stable or improving disease will be randomized to either receive local treatment for their primary tumor (surgery with or without radiation) followed by continued systemic therapy (per MD discretion) or continued systemic therapy alone (per MD discretion).  Patients will be followed every 3 months following randomization for 2 years, and then every 6 months until 5 years from study enrollment and will undergo periodic imaging with CT and bone scan OR PET/CT to monitor disease.  Patients will also be asked to complete QOL questionnaires approximately 5 times during their participation.  Patients will be followed for disease progression and survival.  Patients will be offered the opportunity to participate in an optional sample submission study as part of their participation in the main study.

ClinicalTrials.gov Identifier: NCT01242800
Primary/Site/Co Investigator: Deborah Rubin, MD
Contact: Jennifer Holmes (802) 847-3453
Information: http://www.clinicaltrials.gov/ct2/show/NCT01242800?term=Value+of+Early+Local+Therapy+for+the+Intact+Primary&rank=1
Institution Number: M15-002
Protocol Research Type: Cooperative Group
Status: Active - Closed to Accrual
Study Title:
NSABP B-43 – A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Purpose: This trial is studying radiation therapy with or without trastuzumab to see how well it works in treating women with ductal carcinoma in situ who have undergone lumpectomy. Monoclonal antibodies, such as trastuzumab, can block tumor growth by blocking the ability of tumor cells to grow and spread or by carrying tumor-killing substances to them. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether radiation therapy is more effective with or without trastuzumab in treating ductal carcinoma in situ.
ClinicalTrials.gov Identifier: NCT00769379
Primary/Site/Co Investigator: Ruth Heimann, MD
Contact: Karen Wilson (802) 656-4101
Information: http://www.clinicaltrials.gov/ct2/show/NCT00769379?term=NSABP+B-43&rank=1
Institution Number: CHRMS M71-13, NSABP B-43
Protocol Research Type: Cooperative Group
Status: Active - Closed to Accrual
Study Title:
NSABP B-49 - A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Purpose: Drugs used in chemotherapy work in different ways to stop the growth of breast cancer cells, either by killing the cells or by stopping them from dividing. Giving the drugs in different combinations may kill more breast cancer cells. Giving combination chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in treating women with non-metastatic breast cancer.
ClinicalTrials.gov Identifier: NCT01547741
Primary/Site/Co Investigator: Farrah Khan, MD
Contact: Suzanne Hoeppner (802) 656-9916
Information: www.clinicaltrials.gov/ct2/show/NCT01547741
Institution Number: M12-249 / NSABP B-49
Protocol Research Type: Cooperative Group

Last modified December 09 2014 04:15 PM